Document is current

Article History

Received: 4 March 2024

Accepted: 28 August 2024

First Online: 12 September 2024

Declarations

:

: This retrospective study used de-identified patient-level data and was compliant with the Health Insurance Portability and Accountability Act. Informed consent and institutional review board approval were, therefore, not required.

: CS, CA-S, MK, KR, and DS are employees of Takeda Development Center Americas, Inc. and are Takeda shareholders. JR has served on speakers bureaus for Bristol Myers Squibb and Janssen, and has received consulting fees and served on advisory boards for Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb, Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, Sanofi, Secura Bio, Takeda, and X4 Pharmaceuticals. MSD has received grant support (paid to his institution) and consulting fees from Ascentage Pharma, AstraZeneca, Bristol Myers Squibb, Genentech, MEI Pharma, Secura Bio, and TG Therapeutics, and consulting fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, MingSight, Nuvalent, Secura Bio, Takeda, and TG Therapeutics.

: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit .